Back in May—when concerns about delta variant of COVID-19 were escalating around the world—researchers at the University of Pittsburgh School of Medicine published promising preclinical research on a novel antibody treatment they developed as an inhalable therapy to fight the virus. But they were worried about emerging mutations of the virus, too, so they launched separate studies designed to determine if the drug might be able to tackle those variants, including delta.